Institutional shares held 8.01 Million
67K calls
40.2K puts
Total value of holdings $31.6M
$263K calls
$158K puts
Market Cap $99.8M
25,333,900 Shares Out.
Institutional ownership 31.63%
# of Institutions 64


Latest Institutional Activity in ICAD

Top Purchases

Q1 2025
Schonfeld Strategic Advisors LLC Shares Held: 919K ($3.62M)
Q1 2025
Parkman Healthcare Partners LLC Shares Held: 782K ($3.08M)
Q1 2025
Eam Investors, LLC Shares Held: 288K ($1.14M)
Q1 2025
Universal Beteiligungs Und Servicegesellschaft Mb H Shares Held: 245K ($965K)
Q1 2025
Citadel Advisors LLC Shares Held: 233K ($917K)

Top Sells

Q1 2025
Greenwood Capital Associates LLC Shares Held: 28.5K ($112K)
Q1 2025
Summit Trail Advisors, LLC Shares Held: 75K ($296K)
Q1 2025
Salem Investment Counselors Inc Shares Held: 32.5K ($128K)
Q1 2025
Morgan Stanley Shares Held: 40.1K ($158K)
Q1 2025
Perritt Capital Management Inc Shares Held: 180K ($710K)

About ICAD

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.


Insider Transactions at ICAD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
41.7K Shares
From 2 Insiders
Grant, award, or other acquisition 41.7K shares
Sell / Disposition
18.8K Shares
From 2 Insiders
Grant, award, or other acquisition 18.8K shares

Track Institutional and Insider Activities on ICAD

Follow ICAD INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ICAD shares.

Notify only if

Insider Trading

Get notified when an Icad Inc insider buys or sells ICAD shares.

Notify only if

News

Receive news related to ICAD INC

Track Activities on ICAD